NEW YORK (GBI Research), 12 April 2012 - Major pharmaceutical companies are predicted to lose their footing in the urological disorders market by 2017, a new report by pharmaceutical intelligence expert GBI Research has found. The new report* found that the global urological disorders market will witness multiple patent expiries between 2009 and 2017, including several of the top-selling blockbuster drugs in the Urinary Incontinence (UI), Benign Prostatic Hyperplasia (BPH), Urinary Tract Infection (UTI) and Interstitial Cystitis (IC) markets.
Patent expiries of leading drugs are expected to erode the 72% market share held in 2010 by the top five players in the field, namely Johnson & Johnson, Boehringer Ingelheim, Astellas Pharma, Pfizer, and GlaxoSmithKline.
Important drugs that have recently lost patent protection include Boehringer Ingelheim and Astellas Pharma’s Flomax (tamsulosin) in 2009 and Johnson & Johnson’s Levaquin (levofloxacin) in 2010.
Drugs set to lose patent protection in the coming years include, Pfizer’s Detrol (tolterodine) in Septemeber 2012, Johnson & Johnson’s Doribax in 2015 and Glaxosmithkline’s Avodart in 2015.
The current urological disorders pipeline does offer some promising novel products, namely URG101, YM178, NX-1207, PRX302 and PSD597, indicated for different segments of the market. However, revenue generated from these products is not expected to balance revenue losses incurred from patent expiries, and the market is expected to show slow growth in the forecast period.
Mergers and acquisitions have become popular in the urological disorders market, with increased participation from smaller companies able to rival leading corporations through co-operating with one another. This has led to the decline experienced in recent years by 2010 market leaders Johnson & Johnson and Pfizer.
The global urological disorders market was estimated to be worth $8.1 billion in 2010, following a Compound Annual Growth Rate (CAGR) of 7.9% during 2002-2010, and is forecast to increase at a lower CAGR of 3.4% in the future to exceed $10 billion by 2017.
*Urological Disorders Therapeutics to 2017 – Large Number of Licensing Deals for Approved Products Reflects a Pessimistic R&D Future
The report provides in-depth analysis of the unmet need, drivers, and barriers that impact the global urological disorders market. The report analyzes the markets for urological disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2017 for the key geographies, as well as the leading therapeutic segments. The report also provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that have shaped the global markets. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis conducted by GBI Research’s team of industry experts.
-ABOUT GBI RESEARCH-
GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.
For more information, please contact our Press Office on +44 (0)1204 543 537 or at pr@gbiresearch.com
